HLA-DRB1 antibody (AA 30-58) (FITC)

Catalog No. ABIN1902446

Product Details anti-HLA-DRB1 Antibody (FITC)

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Binding Specificity: AA 30-58

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HLA-DRB1 antibody is conjugated to FITC

Application: Western Blotting (WB), ELISA

Specificity: This HLA-D_1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 30-58 amino acids from the N-terminal region of human HLA-D_1.

Purification: Immunoaffinity purified

Isotype: IgG

Application Details

Application Notes: Approved: ELISA, WB

Usage: The applications listed have been tested for the unconjugated form of this product. Other forms have not been tested.

Comment:

Target Species of Antibody: Human

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: PBS,  pH 7.2, 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Aliquot to avoid repeated freezing and thawing.

Storage: 4 °C,-20 °C

Storage Comment: Short term: store at 4°C. Long term: aliquot and store -20°C for up to 6 months. Avoid freeze-thaw cycles. Protect from light.

Expiry Date: 6 months

Target Details for HLA-DRB1

Target: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Alternative Name: HLA-DRB1 (HLA-DRB1 Products)

Synonyms: MGC108235 antibody, DRB1 antibody, DRw10 antibody, HLA-DR1B antibody, HLA-DRB antibody, SS1 antibody, major histocompatibility complex, class II, DR beta 1 antibody, hla-drb1 antibody, HLA-DRB1 antibody

Background: Name/Gene ID: HLA-DRB1

Synonyms: HLA-DRB1, DRB1, HLA-DR1B, HLA-DRB, Human leucocyte antigen DRB1, MHC class II antigen DRB1*10, MHC class II antigen, MHC class II antigen DRB1*1, HLA-DRB2, Lymphocyte antigen DRB1, SS1

Gene ID: 3123

Pathways: TCR Signaling, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, CXCR4-mediated Signaling Events, Cancer Immune Checkpoints